


Claims

July 1)
A pharmaceutical preparation characterized by a content of at least one compound of general formula (I)



wherein R₁ and R₂ are each independently of each other a straight-chain or branched alkyl residue having 1 to 30 carbon atoms, a straight-chain or branched alkenyl residue having 2 to 30 carbon atoms, a monocyclic or polycyclic alkyl residue having 3 to 30 carbon atoms, a monocyclic or polycyclic alkenyl residue having 4 to 30 carbon atoms, or a monocyclic or polycyclic aromatic residue having 6 to 30 carbon atoms, these residues being optionally substituted by one or several substituents.

July 1)
2) The pharmaceutical preparation according to claim 1, wherein in the compound of formula (I) R₁ and R₂ are a straight-chain C₁₋₁₄ alkyl residue or a C₃₋₁₄ cycloalkyl residue each.

July 1)
3) The pharmaceutical preparation according to claim 1, in the compound of formula (I) wherein R₁ and R₂ are CH₃CH₂ each.

4) The pharmaceutical preparation according to claim 1, wherein the compound of formula (I) is dimethylxanthogenate platinum (II) complex or diethylxanthogenate platinum (II) complex.

5) The pharmaceutical preparation according to claim 1, comprising additionally an immunosuppressive compound selected from the group consisting of cyclosporine, rapamycin, 15-deoxyspergualine, OKT3 and azathioprine.

6) The pharmaceutical preparation according to claim 1, comprising additionally cytokines, interferon or further cytostatic agents.

7) The pharmaceutical preparation according to claim 1, provided in a unit dosage form for administration to a mammal which requires treatment with an anticancer agent.

- 8) The pharmaceutical preparation according to claim 1, further comprising a pharmaceutically compatible inert carrier or a diluent.
- 9) Use of a pharmaceutical preparation according to claim 1 for treating a cancerous disease.
- 10) Use according to claim 9, wherein the cancerous disease is the parvocellular bronchial carcinoma or colorectal carcinoma.
- 11) A process for the production of a pharmaceutical preparation according to claim 1, characterized in that the compound according to formula (I) is mixed with a pharmaceutically compatible carrier or diluent.

卷之三